<DOC>
	<DOC>NCT02320773</DOC>
	<brief_summary>A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.</brief_summary>
	<brief_title>A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice</brief_title>
	<detailed_description>Single arm, hybrid model study, observing patients on Betmiga under conditions of routine clinical practice, with some element of retrospective data collection 2 years prior to enrolment of the study</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients who have been diagnosed with OAB symptoms at Visit 1 of this study. OAB is defined by the International Urogynecological Association (IUGA)/International Continence Society (ICS) 2010 joint report as urinary urgency, with or without urinary incontinence, usually with frequency and nocturia, with no proven infection or other obvious pathology. Patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment. Patients who are currently taking Betmiga®. Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Betanis®</keyword>
	<keyword>Betmiga®</keyword>
	<keyword>Observational</keyword>
	<keyword>Myrbetriq®</keyword>
</DOC>